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Background: Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately
40–50 per million i.e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib
(Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the
standard therapy at first relapse in the UK. Carfilzomib has good activity as a single agent in the relapsed setting,
and it is expected that efficacy will be improved when used in combination with dexamethasone and
cyclophosphamide.
Methods: MUK Five is a phase II open label, randomised, controlled, parallel group, multi-centre trial that will
compare the activity of carfilzomib, cyclophosphamide and dexamethasone (CCD) with that of CVD, given over an
equivalent treatment period (24 weeks), in participants with multiple myeloma at first relapse, or refractory to no
more than 1 line of treatment. In addition, the study also aims to assess the utility of a maintenance schedule of
carfilzomib in these participants. The primary objective of the trial is to assess whether CCD provides non-inferior
activity in terms of ≥ VGPR rates at 24 weeks, and whether the addition of maintenance treatment with carfilzomib
to CCD provides superior activity in terms of progression-free survival, as compared to CCD with no maintenance.
Secondary objectives include comparing toxicity profiles, further summarizing and comparing the activity of the
different treatment arms and analysis of the effect of each treatment arm on minimal residual disease status.
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Discussion: The development of carfilzomib offers the opportunity to further explore the anti-tumour efficacy of
proteasome inhibition and, based on the available evidence, it is important and timely to obtain data on the
activity, toxicity and tolerability of this drug. In contrast to ongoing phase III trials, this phase II trial has a unique
subset of participants diagnosed with multiple myeloma at first relapse or refractory to no more than 1 line of
treatment and will also evaluate the utility of maintenance with carfilzomib for up to 18 months and investigate
minimal residual disease status to provide information on depth of response and the prognostic impact thereof.
Trial registration: The trial is registered under ISRCTN17354232, December 2012.
Keywords: First relapse multiple myeloma, Primary refractory multiple myeloma, Carfilzomib, Phase IIBackground
Multiple myeloma (MM) is a plasma cell tumour with
an annual incidence in the UK of approximately 40–50
per million i.e. about 4500 new cases per annum [1]. For
younger fitter patients the current standard of care is
induction therapy typically using a novel agent-based
regimen consolidated with high-dose melphalan and per-
ipheral blood stem cell rescue (termed autologous stem
cell transplantation, ASCT). For older less fit patients,
frontline regimens include a novel agent along with ste-
roids and an alkylating agent, but without consolidation
with ASCT. With these regimens, the majority of patients
will enter a plateau phase lasting some 3–5 years, however
patients will relapse and require further anti-myeloma
therapy.
Current standard treatment at first relapse in the UK
is the use of bortezomib (Velcade®), commonly with
dexamethasone [2]. Increasingly, a third agent is added,
either an alkylating agent such as cyclophosphamide
(CVD), an anthracycline, doxorubicin (PAD) or thalido-
mide. The triple combination CVD is an effective regi-
men at relapse, producing response rates of up to 70 %
[3–6] and has emerged in recent years as the standard
therapy at first relapse in the UK, with dose adjustments
tailored to age and performance status. Up to 8 cycles are
administered, although many patients have their treat-
ment withdrawn before completing 8 cycles as a conse-
quence of neurotoxicity, more frequently seen with the
intravenous (IV) mode of delivery of bortezomib. Re-
cently, a phase 3 study comparing intravenous (IV) with
subcutaneous (SC) mode of delivery has reported equiva-
lent efficacy with significantly reduced neurotoxicity [7].
The publication of these results has led to widespread
changeover from the IV to the SC use of bortezomib.
The development of carfilzomib, an irreversible epox-
yketone inhibitor of the proteasome, offers the oppor-
tunity to further explore the anti-tumour efficacy of
proteasome inhibition, particularly as some patients have
disease that does not respond to bortezomib, or develop
resistance after initial response. Phase I and II studies have
shown carfilzomib monotherapy can be safely adminis-
tered and produces encouraging response rates. Similarly,when given in combination with lenalidomide and low
dose dexamethasone, carfilzomib is well tolerated, and
there are no significant overlapping toxicities [8–13].
The Myeloma UK (MUK) study, MUK five, has been de-
veloped to further explore carfilzomib combination therapy
in the relapsed or primary refractory setting. Experience
with bortezomib confirms improved efficacy with good
tolerability when used in combination with dexamethasone
and cyclophosphamide (CVD). Carfilzomib has good
activity as a single agent in the relapsed setting, and it
is expected that efficacy will be improved when used in
combination with dexamethasone and a third agent.
Hence it is important and timely to obtain data on the
activity, toxicity and tolerability of Carfilzomib in com-
bination with cyclophosphamide and dexamethasone
(CCD) in the first relapse setting. This triplet regimen
has recently been reported to be a well tolerated and
active regimen in the frontline setting in older patients
not suitable for ASCT [14]. The study has been developed
through the Myeloma UK (MUK) Early Phase Clinical
Trials Network, an innovative collaboration which brings
together clinical specialists and researchers, the pharma-
ceutical industry and NHS regulatory bodies to conduct a




This study will compare the activity of CCD with that of
the current standard therapy at relapse, CVD, given over
an equivalent treatment period (24 weeks), in participants
with multiple myeloma at first relapse, or refractory to no
more than 1 line of treatment. In addition, the study also
aims to assess the utility of a maintenance schedule of
carfilzomib in these participants.
Primary objective
To assess whether CCD provides non-inferior activity
with regard to the short-term outcome measure of ≥
VGPR rates at 24 weeks, and whether the addition of
maintenance treatment with Carfilzomib to CCD provides
superior activity in terms of the longer-term outcome
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to CCD with no maintenance.
Secondary objectives
 To compare the toxicity profile of CCD with that of
CVD, overall and specifically with respect to
peripheral neuropathy
 To explore the non-inferiority of CCD without
maintenance as compared to CVD for longer-term
outcome measure of PFS
 To further summarise the activity of CCD as
compared to CVD with regard to:– Complete response at 24 weeks
– Overall response at 24 weeks and within 12 months
– Maximum response within 12 months
– Maximum response overall
– Time to maximum response
– Duration of response
– Overall survival
– Time to next treatment
 To determine the proportion of participants with a
negative minimal residual disease (MRD) status at
the end of initial treatment phase (24 weeks of
treatment) in both the CVD and CCD arms and to
correlate MRD-negativity at the end of the initial
treatment phase (24 weeks) with PFS for all
participants
 To assess the effect of maintenance Carfilzomib on
MRD status at 6 months and at 12 months post
second randomisation
 To correlate treatment outcomes (Complete
response CR, overall response rate ORR) and PFS
with genetic subgroups
 To summarise treatment compliance.
Study design
The MUK five trial is designed as a phase II randomised,
controlled, parallel group, multi-centre clinical trial for
participants with symptomatic myeloma at first relapse,
or refractory to not more than 1 line of therapy. The
trial has received national research ethics approval from
the NHS National Research Ethics Service London, Ful-
ham (REC Number: 12/LO/1078). A total of 300 partici-
pants will be randomised on a 2:1 basis to either 6 cycles
of CCD or 8 cycles of CVD (both equivalent to 24 weeks
of therapy), with follow-up to disease progression. Par-
ticipants in the CCD arm who, at the end of the initial
6 cycles of CCD do not have evidence of disease progres-
sion, will be randomised to receive maintenance therapy
with Carfilzomib or to receive no further treatment.Participants in the CVD arm will not receive mainten-
ance therapy (Fig. 1). In order to compare the regimens
with regard to activity, the trial has been designed to
incorporate two co-primary endpoints: response and
progression-free survival. This allows the trial to assess
the activity of the two regimens within a fixed period of
24 weeks of treatment, i.e. not incorporating the main-
tenance phase in the CCD arm, and to compare the
activity of the whole CCD regimen with and without
maintenance therapy, and the whole CCD regimen
without maintenance with the CVD regimen by evalu-
ating the longer term endpoint of PFS.
Sample size
The sample size was calculated according to each of the
co-primary endpoints
 ≥ Very good partial response (VGPR)
The primary endpoint analysis is based on a non-
inferiority comparison of CCD vs. CVD. Clinical discus-
sion taking into account recent data anticipates a ≥VGPR
rate of approximately 30–40 % with CVD at first relapse
[4, 15, 16]. Considerable discussion was given to whether
this comparison should be performed as a superiority or
non-inferiority comparison, since CCD is expected to im-
prove ≥VGPR rates by up to 10 %. In this setting, how-
ever, a phase II superiority trial to detect this small
improvement would likely be unfeasible. A non-inferiority
design is therefore used, assuming a ≥VGPR rate of 35 %
with CVD, and a ≥VGPR rate of 45 % with CCD, with a
non-inferiority margin of −5 %. Randomising participants
on a 2:1 basis in favour of CCD, a total of 291 participants
(CCD= 194, CVD= 97) are required to exclude a differ-
ence of −5 % from the 90 % confidence interval with 80 %
power (1-sided 5 % significance level).
 Progression-free survival
The primary PFS comparison will be focused on
those participants undergoing maintenance randomisa-
tion in the CCD arm, to compare maintenance with
carfilzomib vs. no maintenance. It is assumed that median
PFS with CVD with no maintenance will be approximately
14 months from the time of initial treatment [17]. It is
hypothesised that a similar median PFS will be observed
with CCD therapy with no maintenance. It is also antici-
pated that approximately 80 % of participants rando-
mised to receive CCD therapy will be progression-free
at the end of 24 weeks of initial treatment [4]. With
80 % power, a 2-sided alpha of 0.2, and assuming
follow-up of at least 18 months for all participants from
the time of maintenance randomisation, 70 participants
per arm (109 events) are required to detect a hazard
Fig. 1 Trial flow diagram. *All participants who are eligible and provide informed consent will be randomised. A minimum of 140 participants
are required
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PFS of 6 months with Carfilzomib maintenance ther-
apy, from the time of maintenance randomisation. Tak-
ing the required sample size for the response rate
endpoint it is therefore expected that approximately
160 participants will be eligible for maintenance ran-
domisation, providing a sufficient sample size to assess
the maintenance therapy comparison, allowing approxi-
mately 10 % dropout.
Recruitment Process
The trial is expected to take up to 36 months to complete
recruitment. Participants will be recruited from NHS
hospitals throughout the UK which are approved researchsites within the Myeloma UK Early Phase Clinical Trial
Network. Participants will be approached during standard
clinic visits for management of their disease and will be
provided with verbal and written details, in the form of a
participant information sheet. Following information
provision, participants will have as long as they need to
consider participation (normally a minimum of 24 h) and
will be given the opportunity to discuss the study with
their family and other healthcare professionals before they
are asked whether they would be willing to take part in
the study.
Participants who satisfy all the study inclusion criteria
and none of the exclusion criteria listed in Table 1 will
be invited to provide written informed consent.
Table 1 MUK five study inclusion and exclusion criteria
Inclusion criteria for initial randomisation
DISEASE RELATED
- Diagnosed with symptomatic MM (according to IMWG 2003 criteria) and requiring therapy for first relapse or primary refractory disease.
(Participants previously immunofixation negative who are now immunofixation positive need to demonstrate a greater than 5 g/l absolute
increase in paraprotein to be eligible for inclusion).
- Participants with measurable disease as defined by one or more of the following criteria (assessed within 21 days prior to randomisation):
o Serum paraprotein ≥5 g/L (For IgA participants whose disease can only be reliably measured by serum quantitative immunoglobulin
(IgA): ≥ 7.5 g/L)
o Urine Bence Jones Protein: ≥200 mg/24 h
o Serum LC assay: Involved FLC level ≥100 mg/L, provided serum FLC ratio is abnormal
DEMOGRAPHIC
- Age ≥18 years
- Life expectancy ≥6 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0–2
LABORATORY
- Adequate hepatic function, with alanine transaminase (ALT) or aspartate transaminase (AST) <3 times the upper limit of normal and serum direct
bilirubin ≤17 μmol/L (1 mg/100 ml) within 14 days prior to randomisation
- Absolute neutrophil count (ANC) ≥1.0 × 109/L within 14 days prior to randomisation. Growth factor support is not permitted. ANC≥ 0.8 x 109/L is
allowed for participants with racial neutropenia.
- Haemoglobin ≥8 g/dL (80 g/L) within 14 days prior to randomisation (participants may be receiving red blood cell [RBC] transfusions in
accordance with institutional guidelines)
- Platelet count ≥75 × 109/L (≥50 × 109/L if myeloma involvement in the bone marrow is > 50 %) within 14 days prior to randomisation. Platelet
support is not permitted
- Creatinine clearance (CrCl)≥ 20 mL/min or plasma creatinine ≤120 μmol/L within 14 days prior to randomisation, either measured or calculated using
a standard formula (e.g. Cockcroft and Gault)
ETHICAL/OTHER
- Written informed consent
- Female participants of child-bearing potential must have a negative pregnancy test prior to treatment and agree to use dual methods of
contraception for the duration of the study and for 30 days following completion of study. Male participants must also agree to use a barrier method
of contraception for the duration of the study and for 30 days following completion of study if sexually active with a female of child-bearing potential.
Exclusion criteria for initial randomisation
DISEASE RELATED
- Non-secretory multiple myeloma
- Extramedullary plasmacytoma (without evidence of myeloma)
- Received therapy for their first relapsed or primary refractory disease other than local radiotherapy, therapeutic plasma exchange, or
dexamethasone up to a maximum of 200 mg. (Radiotherapy sufficient to alleviate or control pain or local invasion is permitted).
- Previous bortezomib therapy is permitted, providing participant was not refractory (achieved at least a PR, and no disease progression within
6 months of last dose of bortezomib)
- Previous carfilzomib therapy
CONCURRENT CONDITIONS
- Pregnant or lactating females
- Major surgery within 21 days prior to randomisation
- Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomisation
- Known human immunodeficiency virus infection (testing is not required for the trial)
- Active hepatitis B or C infection
- Unstable angina or myocardial infarction within 6 months prior to randomisation, NYHA Class III or IV heart failure, uncontrolled angina, history of
severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute
ischemia or Grade 3 conduction system abnormalities unless participant has a pacemaker, history of torsade de pointe, QTc prolongation
(>450 msec), LVEF <40
- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomisation
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Table 1 MUK five study inclusion and exclusion criteria (Continued)
- Previous or concurrent malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell
skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-
specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such
as localised transitional cell carcinoma of the bladder or benign tumours of the adrenal or pancreas
- Significant neuropathy (Grades 3–4, or Grade 2 with pain) within 14 days prior to randomisation
- Participants with haemorrhagic cystitis
- Any history or known hypersensitivity to any of the study medications or excipients
- Participants undergoing active treatment for infiltrative lung disease
- Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and anti-
platelet options, antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment
- Contraindication to a programme of oral or IV hydration
- Participants with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomisation
- Any other clinically significant medical disease or condition that, in the Investigator’s opinion, may interfere with protocol adherence or a
participant’s ability to give informed consent
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Written informed consent for entry in to the trial must
be obtained and eligibility must be confirmed prior to
randomisation. Randomisation will be administered by
telephone by the University of Leeds Clinical Trials Re-
search Unit (CTRU), using an automated 24 h tele-
phone system. Participants will be randomised on a 2:1
basis to either the CCD or CVD trial arm. A computer
generated minimisation program that incorporates a
random element will be used to ensure treatment
groups are well-balanced for the following characteristics:
β2 microglobulin at trial entry (<3.5, 3.5-5.5, >5.5); prior
bortezomib (Velcade®) treatment (y/ n); prior ASCT (y/n);
timing of first relapse or primary refractory disease
(primary refractory, first relapse: < 12 months, first re-
lapse: ≥ 12 months).
Participants on the CCD arm only, who have no evi-
dence of progressive disease at the response assessment
at the end of CCD therapy, will be randomised again to
receive either carfilzomib maintenance or no mainten-
ance treatment, provided they fulfil the eligibility criteria
listed in Table 2. Participants will be randomised on a
1:1 basis to either carfilzomib maintenance or no main-
tenance. A computer generated minimisation program
that incorporates a random element will be used to
ensure treatment groups are well-balanced for the fol-
lowing characteristics: response category at the end of
treatment with CCD (PR, MR or SD vs. VGPR or CR);
prior ASCT (y/n).
Intervention
Participants randomised to CVD will receive the follow-
ing regimen: bortezomib subcutaneous 1.3 mg /m2 (days
1, 4, 8 and 11), cyclophosphamide oral 500 mg (days 1, 8
and 15), dexamethasone oral 40 mg (days 1, 8 and 15).
The cycle is repeated every 21 days. Response should be
assessed at the end of each cycle and, in the absence ofdisease progression or intolerance, participants should
receive 8 cycles of treatment. Participants randomised to
CCD will receive the following regimen: carfilzomib IV
20 mg/m2(cycle 1, days 1 and 2 only) / 36 mg/m2 (cycle
1, days 8, 9, 15 and 16, and cycle 2 onwards, days 1, 2, 8,
9, 15 and 16), cyclophosphamide oral 500 mg (days 1, 8
and 15), dexamethasone oral 40 mg (days 1, 8, 15 and
22). The cycle is repeated every 28 days. Response
should be assessed at the end of each cycle and, in the
absence of disease progression or intolerance, partici-
pants should receive 6 cycles of treatment.
Participants in the CCD arm, who are randomised to re-
ceive carfilzomib maintenance, will receive carfilzomib IV
36 mg/m2 (days 1, 2, 15 and 16) for 6 months, after which
the frequency of dosing will be reduced to carfilzomib IV
36 mg/m2 (days 1 and 2) for a further 12 months.
Each drug may be reduced due to toxicity. If no reso-
lution of toxicity is seen after adjustment to the lowest
dose level, treatment will be discontinued.
Trial assessments
Baseline investigations are to be performed within
14 days prior to randomisation, after written informed
consent has been obtained. The required baseline as-
sessments include a physical examination, medical his-
tory, ECOG performance status and ISS stage, as well
as haematology, biochemistry, radiological and bone
marrow sample assessments.
Assessments during treatment, including a physical
examination, safety and laboratory tests will be performed
at multiple time-points during cycles 1 – 6 for the CCD
regimen and cycles 1 – 8 for the CVD regimen. Response
assessments will be carried out at the end of treatment
phase (6 months in each arm), according to Inter-
national Myeloma Working Group (IMWG) criteria,
and will include bone marrow examination for MRD
using multi-parameter flow cytometry.
Table 2 Maintenance randomisation inclusion and exclusion
criteria
Inclusion criteria for maintenance randomisation
- Completed at least 24 weeks of CCD treatment in line with the
protocol (must have received a minimum of 5 cycles and achieved
a maximum response to initial therapy).
- No evidence of disease progression
- Adequate hepatic function, with ALT or AST <3 times the upper limit
of normal and serum direct bilirubin ≤42.5 μmol/L (2.5 mg/100 ml)
within 14 days prior to randomisation
- Absolute neutrophil count (ANC) ≥1.0 × 109/L within 14 days prior
to randomisation. Growth factor support received in the previous
cycle of treatment is permissible.
- Haemoglobin ≥8 g/dL (80 g/L) within 14 days prior to randomisation
(participants may be receiving red blood cell [RBC] transfusions in
accordance with institutional guidelines)
- Platelet count ≥75 × 109/L (≥50 × 109/L if myeloma involvement in
the bone marrow is >50 %) within 14 days prior to randomisation.
Platelet support received in the previous cycle of treatment is
permissible.
- Creatinine clearance (CrCl) ≥20 mL/min or plasma creatinine
≤120 μmol/L within 7 days prior to randomisation, either measured
or calculated using a standard formula (eg, Cockcroft and Gault)
- Female participants of child-bearing potential must have a negative
pregnancy test prior to treatment and agree to use dual methods of
contraception for the duration of the study and for 30 days following
completion of study. Male participants must also agree to use a barrier
method of contraception for the duration of the study and for
30 days following completion of study if sexually active with a
female of child-bearing potential.
Exclusion criteria for maintenance randomisation
- Uncontrolled hypertension or uncontrolled diabetes
- Any other clinically significant medical disease or condition that, in
the Investigator’s opinion, may interfere with protocol adherence
- Pregnant or lactating females
- Significant neuropathy (Grades 3–4, or Grade 2 with pain)
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be performed on days 1, 2, 15 and 16 of each cycle (or
days 1 and 2 if administering the reduced schedule) and
will include a physical examination and laboratory tests.
Assessments at 6 and 12 months will also include bone
marrow sampling for MRD assessment.
Assessments at the end of initial and maintenance treat-
ment include a physical examination, laboratory tests and
a bone marrow aspirate (post-initial treatment). Follow-up
will be performed 4-weekly until disease progression, and
will involve a physical examination and laboratory tests.
Outcome measures
The study has two co-primary endpoints, the proportion
of participants achieving at least VGPR 24 weeks post ini-
tial randomisation and progression-free survival. A key
secondary endpoint is the proportion of participants ex-
periencing ≥ grade 3 neuropathy or ≥ grade 2 neuropathy
with pain during the initial treatment period (8 cycles ofCVD or 6 cycles of CCD). All secondary endpoints are
listed in Table 3.
Statistical methods and analysis
Participants will be grouped as follows for analysis:
(a)All participants randomised to the CVD arm in the
initial randomisation
(b)All participants randomised to the CCD arm in the
initial randomisation
(c)Participants in the CCD arm who were, at the
maintenance randomisation, randomised to receive
no maintenance therapy
(d)Participants in the CCD arm who were, at the
maintenance randomisation, randomised to receive
maintenance therapy
(e)Participants in the CCD arm who do not receive
maintenance therapy. This includes participants
who are, at the maintenance randomisation,
randomised to receive no maintenance therapy,
plus those who do not undergo maintenance
randomisation either because of not being eligible
or not being willing. N.B. in order to avoid bias
due to the imbalanced randomisation schedule,
analyses may include all participants in the CCD
arm, adjusting for the effect of maintenance
therapy as appropriate to provide a comparator
group representing CCD arm participants who do
not receive maintenance therapy.
Primary endpoint analysis
The primary endpoint analysis will include all partici-
pants who have received at least one full cycle of their
allocated chemotherapy. Participants who received less
than one full cycle, defined as missing more than 2
doses of either Carfilzomib or bortezomib in cycle 1
and then stopping trial treatment, will be monitored
and analysed separately as applicable. A non-inferiority
analysis of the proportion of participants achieving at
least VGPR 24 weeks post initial randomisation will
compare groups (a) and (b) in terms of the proportion
of participants achieving ≥ VGPR 24 weeks post ran-
domisation, with a null hypothesis of inferiority of the
CCD arm as compared to the CVD arm, and an alter-
native hypothesis of non-inferiority of CCD, using a
pre-specified non-inferiority margin of −5 %. Further
analysis using logistic regression will adjust for the
minimisation factors (β2 microglobulin at trial entry,
prior bortezomib treatment, prior autologous stem cell
transplant, and timing or first relapse or primary re-
fractory disease). Treatment and covariate estimates
with corresponding standard errors, odds ratios, 90
and 95 % confidence intervals and p-values will be
presented.
Table 3 MUK five secondary endpoint analysis
Secondary endpoint Main comparison(s) Analysis method(s)
Key secondary: proportion of participants experiencing≥ grade 3
neuropathy or ≥ grade 2 neuropathy with pain during initial treatment
(a) vs. (b) [S] Logistic regression
(i) Total time spent at each grade of toxicity for≥ grade 3 neuropathy
or≥ grade 2 neuropathy with pain during initial treatment
(a) vs. (b) [NFT] Descriptive summaries
(ii) Complete response rate 24 weeks post initial randomisation (a) vs. (b) [NI] Logistic regression
(iii) Overall response rate 24 weeks post initial randomisation (a) vs. (b) [NI] Logistic regression
(iv) Proportion of participants achieving MRD negative disease at the
end of initial treatment
(a) vs. (b) [NI] Logistic regression
(v) MRD status of participants at 6 and 12 months following second
randomisation and alteration in MRD status
(c) vs. (d) [S] Logistic regression
(vi) PFS by MRD status at the end of initial treatment MRD -ve vs. MRD + ve [S] Kaplan-Meier & log-rank test, Cox PH
(vii) Overall response rate within 12 months of initial randomisation (c) vs. (d), (a) vs. (e) [S] Logistic regression
(viii) Maximum response within 12 months of initial randomisation (c) vs. (d), (a) vs. (e) [NFT] Descriptive summaries
(ix) Maximum response overall (c) vs. (d), (a) vs. (e) [NFT] Descriptive summaries
(x) Time to maximum response (c) vs. (d), (a) vs. (e) [S] Kaplan-Meier & log-rank test, Cox PH
(xi) Duration of response (c) vs. (d), (a) vs. (e) [S] Kaplan-Meier & log-rank test, Cox PH
(xii) Overall survival (c) vs. (d), (a) vs. (e) [S] Kaplan-Meier & log-rank test, Cox PH
(xiii) Time to next treatment (c) vs. (d), (a) vs. (e) [NFT] Kaplan-Meier; Cumulative Incidence Functions
(competing risks)
(xiv) Toxicity overall, and per cycle of treatment (initial and
maintenance treatment)
(a) vs. (b), (c) vs. (d) [NFT] Descriptive summaries, graded by
Common Terminology Criteria for Adverse Events
V4.0
(xv) Treatment compliance (a) vs. (b), (c) vs. (d) [NFT] Descriptive summaries
(xvi) Safety (a) vs. (b), (c) vs. (d) [NFT] Descriptive summaries
NI non-inferiority, S superiority, NFT no formal statistical testing, Cox PH Cox’s proportional hazards model
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analysis of groups (c) and (d). PFS curves will be calcu-
lated using the Kaplan-Meier method and the median
progression-free survival estimates and progression-free
survival estimates at 12 and 24 months with corre-
sponding 80 % and 95 % confidence intervals will be
presented by treatment group. A log-rank test, stratify-
ing for the minimisation factors, will be used to com-
pare PFS between treatment groups. Cox’s proportional
hazards model (if appropriate), adjusting for the mini-
misation factors, will also be used to compare PFS be-
tween the treatment groups. Treatment and covariate
estimates, standard errors, hazard ratios, 80 % and 95 %
confidence intervals, as well as p-values will be pre-
sented. An exploratory non-inferiority comparison will
also be performed to compare groups (a) and (e). If the
main comparison between (c) and (d) shows no evi-
dence of improved PFS for either treatment group, the
superiority analyses described above will also be per-
formed for (a) vs (b).
Analysis of response and PFS will be performed using
the data recorded on the case report form, which will be
centrally reviewed for quality assurance.Secondary endpoint analysis
The main comparisons and analysis methods for each
secondary endpoint are given in Table 3. Short term
endpoints (i.e. those evaluable at 24 weeks post ran-
domisation / the end of initial treatment) generally
compare groups (a) and (b). Longer term endpoints
generally compare groups (c) and (d), and (a) and (e).
The majority of endpoints will be analysed according to
the analysis population, including all participants who
receive at least one cycle of their allocated chemother-
apy, as with the primary endpoint analysis. The safety
population will include all participants who receive at
least one dose of any trial treatment and will be used
for the toxicity and safety endpoints. Treatment com-
pliance will be produced for all participants according
to the trial pathways. Exploratory analyses to investigate
the association between clinical outcomes (ORR and
PFS) and genetic subgroups will also be performed.
Flow cytometry for MRD detection will be performed
as reported by Rawstron et al. [18], with a 0.01 % limit
of detection, assessing 500 000 cells incubated with 6-
color antibody combinations including CD138/CD38/
CD45/CD19 with CD56/CD27 in all cases and CD81/
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defined in a statistical analysis plan prior to any analysis
being undertaken.
Frequency of analyses
A Data Monitoring and Ethics Committee (DMEC) will
be set up to independently review data on safety, activity,
protocol adherence and recruitment. This committee, in
light of this data, and any advice and evidence they wish
to request, will if necessary report to the Trial Steering
Committee (TSC) if there are any concerns regarding
the activity or safety of the trial treatments.
An interim analysis for inferiority will be performed
once half the number of patients has been recruited.
This interim analysis will assess for inferiority of CCD,
as compared to CVD, in terms of the response co-primary
endpoint. If, at the time of this interim analysis, CCD is
found to be significantly inferior as compared to CVD, the
DMEC will report to the TSC with a recommendation of
early trial closure. The analysis will be detailed in a DMEC
Interim Statistical Analysis Plan.
Final analysis is planned to take place in two stages.
Stage 1 of the analysis is planned to take place after all
participants have completed the 24 weeks of initial
treatment and will include the short term endpoints re-
lating to the initial treatment period or 24 weeks post
initial randomisation time-point. Stage 2 of the final
analysis is planned to take place when all participants
have completed their full follow-up. This analysis will
consider all long-term endpoints not included in stage
1 of the analyses.
Discussion
Multiple myeloma is the 17th most common cancer in
the UK, accounting for around 1 % of all new cancer
cases. Myeloma incidence rates have increased overall in
Great Britain since mid-1970s [1]. The majority of pa-
tients will enter a plateau phase lasting some 3–5 years,
with therapies based on thalidomide or alkylating agents.
Patients will relapse and require further anti-myeloma
therapy. The use of bortezomib and lenalidomide has
revolutionised the treatment of relapsed disease with
both drugs being shown to improve response rates,
progression-free and overall survival, when compared to
dexamethasone in randomised clinical trials in relapsed
participants [2].
The triple combination of bortezomib, dexametha-
sone and an alkylating agent, such as cyclophosphamide
(CVD), is an effective regimen at relapse. The develop-
ment of carfilzomib offers the opportunity to further ex-
plore the anti-tumour efficacy of proteasome inhibition.
In phase I and phase II clinical studies, carfilzomib dem-
onstrated robust and durable efficacy and acceptable
safety and tolerability profile in participants with relapseand/or refractory multiple myeloma [19]. Based on the
available evidence, it is important and timely to obtain
data on the activity, toxicity and tolerability of this drug.
In contrast to ongoing phase III trials such as ASPIRE,
FOCUS, ENDEAVOR and CLARION [19], this phase II
trial has a unique subset of participants diagnosed with
multiple myeloma at first relapse or refractory to no more
than 1 line of treatment. The MUK five trial will also
evaluate the utility of maintenance with carfilzomib for up
to 18 months and investigate MRD status to provide infor-
mation on depth of response and the prognostic impact
thereof.
The findings of this trial will inform healthcare profes-
sionals, patients, and their caregivers about the activity
and safety profile of CCD in this setting.
Ethics
The trial has received national research ethics approval
from the NHS National Research Ethics Service London,
Fulham (REC Number: 12/LO/1078)
Consent to participate
All patients provide written informed consent prior to
randomisation in to the trial.
Consent to publish
Not applicable
Availability of data and materials
Not applicable – this is a protocol paper outlining the
study being conducted. All data supporting the develop-
ment of the study is outlined in the manuscript.
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